Royalty Pharma (RPRX) Cash from Operations (2019 - 2026)

Royalty Pharma has reported Cash from Operations for 8 years, with the latest figure at 718233000.0 in Q1 2026.

• Quarterly Cash from Operations rose 20.49% year-over-year to 718233000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2611980000.0 (down 3.28% YoY) and the FY2025 annual result came in at 2489823000.0, down 10.08% from the prior year.
• Cash from Operations slipped to 718233000.0 in Q1 2026 per RPRX's latest filing, from 827148000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1033837000.0 in Q1 2023 and troughed at 363984000.0 in Q2 2025.
• A 5-year average of 653460235.29 and a median of 658209000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations soared 124.62% in 2023, then slumped 44.7% in 2025.
• Over 5 years, Cash from Operations stood at 569931000.0 in 2022, then soared by 35.57% to 772628000.0 in 2023, then retreated by 3.9% to 742525000.0 in 2024, then grew by 11.4% to 827148000.0 in 2025, then fell by 13.17% to 718233000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 718233000.0, 827148000.0, and 702615000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.